<DOC>
	<DOCNO>NCT00409721</DOCNO>
	<brief_summary>The purpose study investigate effect memantine ALS patient use functional outcome measure .</brief_summary>
	<brief_title>The Effect Memantine Functional Outcomes Motor Neuron Degeneration Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>El Escorial Classification laboratory support probable , probable , definite ALS Age 18 80 year , ALS symptoms 3 year , FVC great equal 60 % predict , Riluzole na√Øve stable dose Riluzole least 2 month , Patients must ability attend monthly study visit Edmonton Calgary , Alberta Presence significant sensory abnormality , dementia , neurologic disease , uncompensated medical illness psychiatric illness Female patient breastfeed Use concurrent investigational drug , Patient unlikely comply study requirement Poor adherence study protocol runin phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>MND</keyword>
	<keyword>Memantine</keyword>
</DOC>